Fig. 2 | npj Aging and Mechanisms of Disease

Fig. 2

From: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy

Fig. 2

Changes in coronary artery calcium score (Agatston score) at the baseline and at follow-up for the duration of no-statin-no-PCSK9 inhibitor therapy (a, b) (n = 10) and in monotherapy (c, d) (n = 15) in the paired longitudinal study. Changes in coronary artery calcium Score (Agatston score) before and after add-on PCSK9 inhibitor to the statin therapy (e, f) (n = 16) in the paired longitudinal study. Data were expressed as the median and 10th–90th percentiles. The horizontal line inside the box is the median. Boxes represent the interquartile range (25th–75th percentile). Whiskers represent the 10th–90th percentile. The x marks in the box indicate the average. a, c, e: linearized data, b, d, f: log-transformed data. *P < 0.05 vs. baseline for the no-statin-no-PCSK9 inhibitor therapy by the non-parametric Wilcoxon signed-rank test. **P < 0.01 vs. baseline for the statin monotherapy by the non-parametric Wilcoxon signed-rank test. ***P < 0.05 vs. before add-on PCSK9 inhibitor to statin therapy by the non-parametric Wilcoxon signed-rank test

Back to article page